Characterization of postsynaptic β-adrenergic receptors and presynaptic muscarinic cholinergic receptors in the rat spleen

The β-adrenergic and muscarinic cholinergic receptors in the splenic homogenates of control and 6-hydroxydopamine (6-OHDA) treated rats were characterized. The specific binding of [³H]dihydroalprenolol (DHA) and [³H]quinuclidinyl benzilate (QNB) in the rat spleen were saturable and of high affinity and showed pharmacological specificity of splenic β-adrenergic and muscarinic cholinergic receptors. Following 6-OHDA treatment, the Bmax value for specific [³H](-)DHA binding to the rat spleen was significantly increased by 26 percent and 22 percent compared to control at 2 and 3 weeks without a change in the Kd. In contrast, there was a 38 percent decrease in the Bmax for [³H](-)QNB in the 6-OHDA treated rat spleen at 2 and 3 weeks respectively without a change in the Kd. The Bmax value at 5 weeks was significantly greater than that at 2 or 3 weeks. The splenic norepinephrine (NE) concentration was markedly reduced by the 6-OHDA treatment at 1 to 3 weeks, while there was a significant recovery in the splenic NE concentration at 5 weeks. Thus, our results strongly suggest that we are biochemically localizing muscarinic cholinergic receptors on the sympathetic nerves of the rat spleen and that the β-adrenergic receptors of the spleen are localized postsynaptically.     

Differential roles of estrogen receptors α and β in control of B-cell maturation and selection

It is clear that estrogen can accelerate and exacerbate disease in some lupus-prone mouse strains. It also appears that estrogen can contribute to disease onset or flare in a subset of patients with lupus. We have previously shown estrogen alters B-cell development to decrease lymphopoiesis and increase the frequency of marginal zone B cells. Furthermore, estrogen diminishes B-cell receptor signaling and allows for the increased survival of high-affinity DNA-reactive B cells. Here, we analyze the contribution of estrogen receptor α or β engagement to the altered B-cell maturation and selection mediated by increased exposure to estrogen. We demonstrate that engagement of either estrogen receptor α or β can alter B-cell maturation, but only engagement of estrogen receptor α is a trigger for autoimmunity. Thus, maturation and selection are regulated differentially by estrogen. These observations have therapeutic implications.     

Expression and function of heregulin-α and its receptors in the mouse mammary gland

Heregulin-α (HRGα) is a cytokine secreted by the mammary mesenchyme, adjacent to lobuloalveolar structures. To understand the role of HRGα and its receptors in mammary glands, and the underlying mechanisms, we performed this study to determine the expression and localization of HRGα and its receptors ErbB2 and ErbB3. We also determined the role of HRGα in the development of mammary glands, β-casein expression and secretion, Rab3A protein expression and the phosphorylation of HRGα signaling molecules using confocal laser scanning microscopy, tissue culture, capillary electrophoresis, Western blotting and enzyme-linked immunosorbent assays. We found that a peak was on pregnancy day 15. Changes of ErbB2 and ErbB3 expression were positively and linearly correlated with HRGα, indicating that HRGα positively regulates ErbB2 and ErbB3 expression. During pregnancy, HRGα enhanced the phosphorylation of STAT5, p42/p44, p38, PKC and Rab3A protein expression, stimulated the proliferation and differentiation of the ductal epithelial cells of mammary glands, and increased and maintained the expression and secretion of β-casein. During lactation, HRGα enhanced the phosphorylation of STAT5 and p38, inhibited the phosphorylation of PKC and Rab3A protein expression, maintained the morphology of the mammary glands and increased the secretion of lactoprotein to reduce the expression of β-casein in mammary epithelial cells. During involution, HRGα induced the phosphorylation of STAT3 and Rab3A protein expression, and inhibited the phosphorylation of PKC to stimulate the degeneration of mammary epithelial cells. It also inhibited the secretion of β-casein, resulting in increased levels of β-casein in mammary epithelial cells.     

The known interactome of PTPIP51 in HaCaT cells—Inhibition of kinases and receptors

Protein tyrosine phosphatse interacting protein (PTPIP51) is involved in the modulation of the mitogen activated protein kinase (MAPK) signaling pathway. Up to now, less is known about the regulation of this modulation. A recent study hinted to the phosphorylation status of PTPIP51 being essential for correct regulation of PTPIP51 function.In this study we investigate the phosphorylation status of PTPIP51 under the inhibition of the main interacting kinases and phosphatases of PTPIP51. c-Src was inhibited by Dasatinib, EGF receptor by Gefitinib, protein kinase C by staurosporine, protein kinase A by RpcAMPs and PTP1B by its specific inhibitor. Furthermore, a combination of PP2 with Gefitinib and RpcAMPs was used, respectively. The data were acquired for non-EGF and EGF treated HaCaT cells.All cells were analyzed relative to the subcellular distribution and change in the amount of tyrosine 176 phosphorylated PTPIP51. Furthermore, the protein interactions were assayed by duolink proximity ligation assay.HaCaT cells submitted to the respective inhibitor displayed a subcellular redistribution of tyrosine 176 phosphorylated PTPIP51 depending on the applied inhibitor. Yet, the amount of tyrosine 176 phosphorylated PTPIP51 remained unchanged by inhibitor treatment except for Gefitinib and simultaneous PP2 and Gefitnib treatment in non EGF-stimulated cells, but was elevated if cells were also EGF stimulated, in control and inhibitor treated cells. Interestingly, the interaction with EGFR, 14-3-3, Raf-1, c-Src, PTP1B, PKA and PKC was influenced by the application of inhibitors. Also EGF application resulted in a sharp drop of the PTPIP51 interaction with the MAPK pathway (e.g. Raf-1) in the control group.Summarizing these new findings, we postulate that PTPIP51 is regulated by its phosphorylation status combined with a thereby induced subcellular redistribution. In addition, the EGF receptor regulates PTPIP51 interaction with Raf-1 by its phosphorylation, thus preventing an overshooting activation of the MAPK pathway.     

The role of γ-aminobutyric acid and its receptors in the nucleus of basal optic root in pigeons

The effects of γ-aminobutyric acid (GABA) and its antagonists bicuculline and 2-hydroxysaclofen on neuronal firings in the nucleus of basal optic root (nBOR) in pigeons were studied by using extracellular recording and microiontophoretic techniques. The results suggest that GABA may be an inhibitory neurotransmitter or modulator within nBOR, functioning by means of main mediation of GABAA receptors and of minor mediation of GABAB receptors. Furthermore, GABA and its GABAA receptors are involved in the modulation of directional selectivity in part of nBOR neurons.     

Direct insertion and fluorescence studies of rhodamine-labeled β-adrenergic receptors in cell membranes

Summary Previous studies utilizing the fluorescence of propanolol as a probe for the beta-adrenergic receptor showed that this receptor is motionally constrained. To further study the betaadrenergic receptorin situ we have reinserted rhodamine-labeled beta-receptors into cell membranes. This report presents documentation of their insertion and physiologic viability. Beta-receptors were purified by affinity chromatography (10,000-fold), then fluorescently labeled with tetramethyl rhodamine isothiocyanate, repurified (55,000-fold) and incubated with rat pancreatic islet cells. The binding of³H-dihydroalprenolol by these cells was increased from aB _max of 168±2 to 309±20 fmol/mg protein with no change inK _d . Various treatments which remove peripheral membrane proteins, e.g. NaOH, lithium diiodosalicylate, and trypsinization, did not alter binding by the cells with inserted receptors indicating that the receptors inserted into cell membranes. In islet cells treated with Koshland's reagent I, beta-adrenergic binding was completely abolished, but following incubation with isolated beta-receptors, the cells bound beta-adrenergic radioligand with aB _max of 100 fmol/mg protein, indicating functionality on the part of the inserted receptors. Furthermore, insertion of isolated receptors into frog erythrocytes resulted in increased production of cAMP in response to added isoproterenol. In pancreatic islet cells, incubation with labeled receptors caused the fluorescence to shift in wavelength with increased intensity indicating a shift from an aqueous to a lipid environment, probably into the membrane. Using fluorescence (P), it was found that the inserted receptors became motionally constrained to aP of 0.38 (limitingP _o=0.42) during the first 15 min, remaining so for at least 2 hr. Colchicine (5 g/ml) caused a decrease inP to 0.18 indicating release of constraint. Isoproterenol (10^–5M) caused a rapid decrease toP=0.15. This effect was blocked by propranolol. Propranolol itself (10^–5M) had no effect. These results indicate that the labeled receptors rapidly insert into cell membranes and also support the view that agonist activation of the receptor causes an increase in receptor mobility, presumably due to release of constraint from cytoskeleton elements.     

Activation and differentiation of sexual behavior and translocation of hypothalamic estrogen receptors in rats by 6α-fluorotestosterone

Androgens classified as nonaromatizable in placental assay systems typically do not mimic testosterone's effects on sexual behavior in rats. 6α-Fluorotestosterone is an exception. To pursue this challenge to the aromatization hypothesis, we compared several behavioral and neuroendocrine effects of 6α-fluorotestosterone propionate (6α-fluoro-TP) with those of testosterone propionate (TP). Even at a very low dose (6.25 μg/100 g/day), 6α-fluoro-TP maintained most aspects of male sexual behavior as well as TP. It was slightly less potent than TP for inhibiting gonadotropin secretion (testicular development) in prepubertal males. Given neonatally, these androgens were equally likely to induce anovulatory sterility. 6α-Fluoro-TP defeminized sexual development in females and neonatally castrated males half as effectively as TP based on lordosis:mount ratios following estrogen and progesterone therapy in adulthood. Neither androgen masculinized sexual behavior. The behavioral effects of 6α-fluoro-TP correspond to its ability to inhibit cell nuclear accumulation of 17β-[³H]estradiol in the hypothalamuspreoptic area. When injected on a schedule like that used to activate male sexual behavior, the two androgens reduced estrogen uptake equally. When injected into adult castrates on a schedule like that used to defeminize sexual development, 6α-fluoro-TP blocked estrogen uptake half as well as TP. 6α-Fluorotestosterone did not alter estrogen uptake when injected simultaneously with 17β-[³H]estradiol. These data suggest that 6α-fluorotestosterone activates male behavior and defeminizes development because it translocates estrogen receptors in the brain, probably via an aromatized metabolite. Hence androgen aromatizability in the placenta may not reflect neural metabolism and cannot predict the behavioral or neuroendocrine effects of androgens.     

Differential maturation of μ and δ opioid receptors in the chick embryonic brain

The developmental profiles of the binding of and opiate receptors agonists was investigated using the chick embryo brain. Binding of opioids was performed at embryonic days 5, 6, 15, 18, and 20 in the developing chick embryo brain. [³H]dihyromorphine was used as a ligand and with 5×10^–7 M levorphanol for non-specific binding, and [³H](d-Ala²-d-Leu⁵)-enkephalin was used as a with 5×10^–7 M (d-Ser-Gly-Phe-Leu-Thr)-enkephalin for non-specific binding. Crude membranes were prepared from whole brain at days, 5, 6 and cerebral hemispheres at days 15, 18, and 20 of embryonic age. Both and opiate receptors were present during early embryogenesis and as early as day 5. Analysis of binding sites revealed high and low affinity sites during early embryogenesis but only one site. By 18 days of embryonic age, only one site remained. This developmental change is interpreted as a transitory state of the receptor to the adult pattern. The presence of only one site is constant throughout embryonic age; it is high during early embryogenesis reaching a lower level by 18 days. The presence of a dual binding site pattern for the receptor in early embryogenesis is implicated to have a functional significance in the pluripotential role of the endogenous opioids in early development.     

Distribution of immune cells and expression of interleukin receptors in ileal Peyer’s patches of calves

Newborn calves lack a mature immune system. The immune system develops with age, but the role of the expression of cytokine receptors in the development of immune cells of Peyer’s patches (PPs) in the intestines of calves in the first 2 months has not yet been elucidated. In this study, the distribution of immune cells and the expression of interleukin (IL) receptors (R) in the ileal PPs of newborn and 2-month-old calves were investigated immunohistochemically with monoclonal antibodies against bovine CD4, CD8, IgM, γδTCR, T19, WC3, WC5, and WC6 antigens. The expression of ILRs was examined with antibodies against CD25 (IL-2Rα), IL-2Rγ, IL-4R, IL-6R, IL-10R, and IL-13R antigens. CD4⁺, CD8⁺, γδTCR⁺, T19⁺, and WC6⁺ cells were found to be more widely distributed in the ileal PPs of 2-month-old calves than in those of newborn calves. Moreover, the expression of CD25 (IL-2Rα), IL-4R, and IL-13R in the ileal PPs of 2-month-old calves was more prominent than that in newborn calves. These data suggest that the immune system of calves at 2 months of age is developed by reactions to foreign antigens and aging.     

Axonal transport of muscarinic receptors in vesicles containing noradrenaline and dopamine-β-hydroxylase

Presynaptic muscarinic receptors labeled with [³H]dexetimide and noradrenaline in dog splenic nerves accumulated proximally to a ligature at the same rate of axonal transport. After fractionation by differential centrifugation, specific [³H]quinuclidinyl benzilate or [³H]dexetimide binding revealed a distribution profile similar to that of dopamine-β-hydroxylase and noradrenaline. Subfractionation by density gradient centrifugation showed two peaks of muscarinic receptors; the peak of density 1.17 contained noradrenaline and dopamine-β-hydroxylase whereas that of density 1.14 was devoid of noradrenaline. Therefore the foregoing experiments provide evidence that presynaptic muscarinic receptors are transported in sympathetic nerves in synaptic vesicles which are similar to those containing noradrenaline and dopamine-β-hydroxylase. This suggests a possible coexistence of receptor and neurotransmitter in the same vesicle.     

Supportive or detrimental roles of P2Y receptors in brain pathology?—The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies

This review describing the role of P2Y receptors in neuropathological conditions focuses on obvious differences between results demonstrating either a role in neuroprotection or in neurodegeneration, depending on in vitro and in vivo models. Such critical juxtaposition puts special emphasis on discussions of beneficial and detrimental effects of P2Y receptor agonists and antagonists in these models. The mechanisms reported to underlie the protection in vitro include increased expression of oxidoreductase genes, like carbonyl reductase and thioredoxin reductase; increased expression of inhibitor of apoptosis protein-2; extracellular signal-regulated kinase- and Akt-mediated antiapoptotic signaling; increased expression of Bcl-2 proteins, neurotrophins, neuropeptides, and growth factors; decreased Bax expression; non-amyloidogenic APP shedding; and increased neurite outgrowth in neuronal cells. Animal studies investigating the influence of P2Y receptors in middle cerebral artery occlusion (MCAO) models for stroke prove beneficial effects of P2Y receptor antagonists. In MCAO mice and rats, the application of broad-range P2 receptor antagonists decreased the infarct volume and improved neurological outcome. Moreover, antagonists of the P2Y₁ receptor, one of the most abundant P2Y receptor subtypes in brain tissue, decreased neuronal loss and improved spatial memory in rats after traumatic brain injury (TBI). Currently available data show a discrepancy between in vitro and in vivo models concerning the benefits of P2Y receptor activation in pathological conditions. In vitro models demonstrate protection by P2Y receptor agonists, but in vivo P2Y receptor activation deteriorates the outcome after MCAO and controlled cortical impact brain injury, a TBI model. To broaden the scope of the review, we additionally discuss publications that demonstrate detrimental effects of P2Y receptor agonists in vitro and publications showing protective effects of agonists in vivo. All these studies help to better understand the significant role of P2Y receptors especially in stroke models and to develop pharmacological strategies for the treatment of stroke.     

Distribution and hormonal regulation of membrane progesterone receptors β and γ in ciliated epithelial cells of mouse and human fallopian tubes

Background  

The controlled beating of cilia of the fallopian tube plays an important role in facilitating the meeting of gametes and subsequently transporting the fertilized egg to its implantation site. Rapid effects of progesterone on ciliary beat frequency have been reported in the fallopian tubes of cows, but the identity of the receptors mediating this non-genomic action of progesterone is not known. We recently identified a member of the non-genomic membrane progesterone receptor family, mPR gamma, as a candidate for mediating these actions of progesterone. Here, we investigated the possible presence of a related receptor, mPR beta, in the fallopian tubes of mice and women as well as the possible hormonal regulation of mPR beta and gamma.     

Estrogen and progesterone receptors in mammary tumors induced in rats by simultaneous administration of 17ß-estradiol and progesterone

Mammary tumors were promoted in male rats of the Wistar WAG strain by continuous and simultaneous administration of 17ß-estradiol and progesterone. Tumor induction and growth were dependent on estradiol and on progesterone. Their histological features were comparable with those of human breast cancers. Hormone receptors were present in tumor cells. Estradiol receptor was found in 95% of them, at a higher level in nuclei than in cytosol. Progesterone receptor was present in 75% of tumors. In all cases, the level of androgen receptor was low.     

Are G-protein-coupled receptors involved in mediating larval settlement and metamorphosis of coral planulae?

Larvae of the scleractinian coral Pocillopora damicornis are induced to settle and metamorphose by the presence of marine bacterial biofilms, and the larvae of Montipora capitata respond to a combination of filamentous and crustose coralline algae. The primary goal of this study was to better understand metamorphosis of cnidarian larvae by determining what types of receptors and signal-transduction pathways are involved during stimulation of metamorphosis of P. damicornis and M. capitata. Evidence from studies on larvae of hydrozoans suggests that G-protein-coupled receptors (GPCRs) are good candidates. Settlement experiments were conducted in which competent larvae were exposed to neuropharmacological agents that affect GPCRs and their associated signal-transduction pathways, AC/cAMP and PI/DAG/PKC. On the basis of the results of these experiments, we conclude that GPCRs and these pathways do not mediate settlement and metamorphosis in either coral species. Two compounds that had an effect on both species, forskolin and phorbol-12-myristate-13-acetate (TPA), may be acting on other cellular processes not related to GPCRs. This study strengthens our understanding of the underlying physiological mechanisms that regulate metamorphosis in coral larvae.     

Role of prions in neuroprotection and neurodegeneration: A mechanism involving glutamate receptors?

There is increasing evidence that cellular prion protein plays important roles in neurodegeneration and neuroprotection. One of the possible mechanism by which this may occur is a functional inhibition of ionotropic glutamate receptors, including N-Methyl-D-Aspartate (NMDA) receptors. Here we review recent evidence implicating a possible interplay between NMDA receptors and prions in the context of neurodegenerative disorders. Such is a functional link between NMDA receptors and normal prion protein, and therefore possibly between these receptors and pathological prion isoforms, raises interesting therapeutic possibilities for prion diseases.Key words: NMDA, NR2D, glutamate, neuroprotection, calciumPrions are most often discussed in the context of transmissible spongiform encephalopathies (TSEs) which encompass a range of neurological disorders that include human Creutzfeldt-Jakob disease (among others), sheep scrapie and bovine spongiform encephalopathy.^1,2 It is well established that these disorders arise from a progressive conversion of the normal, mainly helical form of cellular prion protein (PrP^C) into a different PrP^Sc protein conformation with a high beta sheet content.³ In their PrP^Sc form, prions act as templates that catalyze misfolding of PrP^C to produce increasing levels of PrP^Sc, which likely represents several or even many different conformational states of the same source protein, resulting in diverse clinical phenotypes. This in turn leads to accumulation of PrP^Sc deposits in the brain that can appear as aggregates and amyloid-like plaques⁴ and which disrupt normal neurophysiology.⁵ While the neuropathology of TSE''s has been explored in great detail dating back to the 1920s,⁶ less effort has perhaps been expended on understanding the cellular and physiological function of PrP^C which is ubiquitously expressed, and found even in simple organisms.^5,7,8 A number of mouse lines either lacking PrP^C or overexpressing PrP^C have been created, including the widely used Zurich I PrP^C knockout strain.^9,10 Despite the wide distribution of PrP^C in the mammalian CNS, it perhaps surprisingly has only a relatively mild behavioral phenotype that appears to include some deficits in spatial learning at the behavioral level^11,12 as well as alterations in long term potentiation at the cellular level.^13–17 In addition, it has been shown that these mice show an increased excitability of hippocampal neurons.^13,18–20 In contrast, deletion of certain parts of the PrP^C protein in vivo can have serious physiological consequences. For example, deletion of a stretch of amino acids between just upstream of the octarepeat copper binding motifs produces a lethal phenotype, that can be rescued by overexpression of increasing levels of normal PrP^C.^21,22 Of particular note, these deletion mutants show degeneration of axons and myelin, both in the CNS and in peripheral nerves; indeed some mutants show a predilection for axomyelinic degeneration with little neuronal pathology,²¹ suggesting that certain mutated forms of PrP have a direct toxic effect on oligodendrocytes and/or myelin.²³ Moreover, activation of the Dpl1 gene in mice lacking PrP^C leads to an ataxic phenotype, that is not observed in the presence of PrP^C.²⁴ Collectively, this indicates that PrP^C may act in a protective capacity and in contrast, certain abnormal forms of PrP are “toxic”, promoting much more injury to various elements of the CNS and PNS than outright absence of wild-type PrP^C.This notion is further corroborated by a number of studies in PrP^C knockout mice, both in vivo and in cell culture models. Cultured hippocampal neurons from PrP^C null mice display greater apoptosis during oxidative stress.²⁵ Moreover, overexpression of PrP^C in rats protects them from neuronal damage during ischemic stroke, whereas PrP^C null mice show greater damage.^27–29 When PrP^C null mice are subjected to different types of seizure paradigms, they showed increased mortality and increased numbers of seizures.³⁰ This increased neuronal damage can be diminished by the NMDA receptor blocker MK-801,³¹ potentially implicating glutamate receptors in this process. Finally, it was recently shown that the absence of PrP^C protein protects neurons from the deleterious effects of beta amyloid, a protein involved in Alzheimer disease.³² It is important to note that NMDA receptors have been implicated in seizure disorders and in cell death during ischemic stroke.^33–35 Indeed, our own work has shown that NMDA receptors expressed endogenously in myelin contribute to myelin damage and may be one of the first steps leading to demyelination.³⁶ Furthermore, the NMDA receptor blocker memantine is used to treat Alzheimer disease, implicating NMDA receptors. The observations above suggest that there may be an interplay between NMDA receptor activity and the physiological function of PrP^C. In support of this hypothesis, our recent work has directly identified a common functional and molecular link between NMDA receptors and PrP^C.³⁷ Brain slices obtained from Zurich I PrP^C null mice showed an increased excitability of hippocampal slices, which could be ablated by blocking NMDA receptor activity with amino-5-phosphonovaleric acid. Removal of extracellular magnesium ions to enhance NMDA receptor activity resulted in stronger pro-excitatory effects in slices and cultured neurons from PrP^C null mice compared with those from normal animals. Synaptic recordings indicate that the amplitude and duration of NMDA mediated miniature synaptic currents is increased in PrP^C null mouse neurons, and evoked NMDA receptor currents show a dramatic slowing of deactivation kinetics in PrP^C null mouse neurons. The NMDA current kinetics observed in these neurons were qualitatively consistent with NMDA receptors containing the NR2D subunit.³⁸ Consistent with a possible involvement of NR2D containing receptors, siRNA knockdown of NR2D normalized current kinetics in PrP-null mouse neurons. Furthermore, a selective co-immunoprecipitation between PrP^C and the NR2D, but not NR2B subunits, was observed. This then may suggest the possibility that under normal circumstances, PrP^C serves to suppress NR2D function, but when PrP^C is absent, NR2D containing receptors become active, and because of their slow kinetics, may contribute to calcium overload under circumstances where excessive (or even normal) levels of glutamate are present. This would include conditions such as epileptic seizures, ischemia and Alzheimer disease, thus providing a possible molecular explanation for the link between PrP^C and neuroprotection under pathophysiological conditions. Indeed, NMDA promoted greater toxicity in PrP^C null mouse neurons, and upon injection into brains of PrP^C null mice. It is interesting to note that one of the major NMDA receptor subtypes expressed in myelin is NR2D, thus bridging the observations of Micu et al.³⁶ of NMDA receptor mediated cell death in ischemic white matter, and those of Baumann and colleagues²¹ showing that PrP^C deletion mutants can cause damage to myelin.How might PrP^C deletion mutants affect neuronal survival? One possibility may be that these deletion mutants compete with normal PrP^C for NMDA receptors, but are unable to functionally inhibit them. Alternatively, it is possible that the PrP^C deletion mutants, by virtue of binding to the receptors, may in fact increase receptor activity, thus causing increased cell death. In both cases, increasing the expression of normal PrP^C would be expected to outcompete the deletion variants, thus reestablishing the protective function. A similar mechanism could perhaps apply to TSEs. It is possible that the PrP^Sc form, perhaps in a manner reminiscent of the PrP^C deletion mutants, may be unable to inhibit NMDAR function, or perhaps would even enhance it. Any excess glutamate that may be released as a result of cell damage due to PrP^Sc aggregates, or even normally released amounts glutamate during the course of physiological neuronal signaling, could be sufficient to cause NMDAR mediated cell death and neuronal degeneration. In this context, it is interesting to note that chronic administration of the weakly NR2D selective inhibitor memantine delays death as a consequence of scrapie infection in mice.³⁹ In the context of Alzheimer disease, binding of PrP^C to beta amyloid may prevent the inhibitory action of PrP^C on NMDA receptor function, thus increasing NMDA receptor activity and promoting cell death. This then may perhaps explain the beneficial effects of memantine in the treatment of Alzheimer disease.In summary, despite the fact that PrP^C is one of the most abundantly expressed proteins in the mammalian CNS, its physiological role is uncertain. Recent observations from our labs have established an unequivocal functional link between normal prion protein and the ubiquitous excitatory NMDA receptor. Thus, one of the key physiological roles of PrP^C may be regulation of NMDA receptor activity. The presence of abnormal species of prion protein, whether acquired via “infection”, spontaneous conformational conversion or genetically inherited, may in turn alter normal function and regulation of NMDA receptors, leading to chronic “cytodegeneration” of elements in both gray and white matter regions of the CNS. This key functional link between PrP and glutamate receptors may provide our first opportunity for rational therapeutic design against the devastating spongiform encephalopathies and potentially other neurodegenerative disorders not traditionally considered as TSE''s.     

β-Adrenergic receptors in innervated and denervated skeletal muscle

In order to determine if the development of β-adrenergic receptors may explain the catecholamine evoked contracture of denervated mammalian skeletal muscle, the binding capacities and dissociation constants of β-adrenergic receptors of innervated and denervated rat skeletal muscle membrane preparations were determined by using [³H] dihydroalprenolol. The dissociation constants of [³H] dihydroalprenolol binding to innervated and denervated muscle microsomal suspensions were similar. The maximal number of binding sites increased from 27 pmol/g protein to 85 pmol/g protein following 25 days denervation. These results suggest that motor nerve may be involved in part, in the regulation of β-adrenergic receptors in skeletal muscle membrane preparations.     

Expression pattern of estrogen receptors α and β and G-protein-coupled estrogen receptor 1 in the human testis

Estrogen signaling is considered to play an important role in spermatogenesis, spermiogenesis and male fertility. Estrogens can act via the two nuclear estrogen receptors ESR1 (ERα) and ESR2 (ERβ) or via the intracellular G-protein-coupled estrogen receptor 1 (GPER, formerly GPR30). Several reports on the localization and expression of all three receptors in the human testis have been published but are controversial particularly in case of ERα. Contrary to previous studies, we decided therefore to evaluate expression of all three receptors in the testis by a number of different methods and in comparison with MCF-7 cells. Using qPCR, we could show that mRNA expression of ERα is considerably lower and expression of ERβ and GPER much higher in the testis than in MCF-7 cells. RT-PCR after laser-assisted microdissection of tubular and interstitial compartments from normal and Sertoli cell only syndrome testes plus in situ hybridization and immunohistochemical analyses of the same samples demonstrated that there is very low expression of ERα in germ cells and in single interstitial cells, very high expression of ERβ in germ cells and Sertoli cells and high expression of GPER in interstitial cells and less in Sertoli cells.